Loading
Led CLARINET, which showed lanreotide slows tumour growth and made somatostatin analogues first-line antiproliferative therapy for NETs.
Martyn Caplin (Royal Free Hospital, London) was principal investigator of CLARINET, the trial showing lanreotide markedly prolongs progression-free survival in non-functioning gastroenteropancreatic neuroendocrine tumours, establishing somatostatin analogues as antiproliferative therapy rather than only symptom control. He leads one of Europe's largest NET centres and has chaired the European Neuroendocrine Tumor Society.
| Title | Journal | Year |
|---|---|---|
| Lanreotide in metastatic enteropancreatic neuroendocrine tumors (CLARINET) | NEJM | 2014 |
| Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study | Endocrine-Related Cancer | 2016 |
Shares Somatostatin receptor 2, Neuroendocrine tumours and the tag neuroendocrine.
Shares Somatostatin receptor 2, Neuroendocrine tumours and the tag neuroendocrine.
Shares Neuroendocrine tumours and the tag neuroendocrine.
Shares Neuroendocrine tumours and the tag neuroendocrine.
Shares Neuroendocrine tumours and the tag uk.
Shares Royal Free Hospital, Royal Free London NHS Foundation Trust and the tag uk.